Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial

November 13, 2025 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Chimeric Therapeutics (ASX: CHM) has reported encouraging new data from its ongoing Phase 1/2 clinical trial of CHM CDH17, a next-generation CAR-T therapy targeting gastrointestinal cancers. …

Subscribe now to continue reading.

Latest Video

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race
November 11, 2025 - Latest News
Vaxxas appoints global vaccine leader to board as needle-free patch moves toward market
November 10, 2025 - Australian Biotech
CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'
November 11, 2025 - Latest News
Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'
November 11, 2025 - Latest News
New Zealand accelerates medicines reform with major regulatory changes
November 12, 2025 - Latest News

Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial

This is a preview of subscriber content

Latest Video

Most Read

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race

Vaxxas appoints global vaccine leader to board as needle-free patch moves toward market

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

New Zealand accelerates medicines reform with major regulatory changes

New Stories

Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial

Australia joins global WHO task force to tackle antimicrobial resistance

New post-market review workplan focuses on real-world data and patient outcomes

Government adds new first-line treatment to the PBS for deadly blood cancer

RAGE Biotech raises $29 million and appoints new leadership to advance precision RNA therapeutics

Nanosonics names new North American president ahead of CORIS launch

Australians open to AI in healthcare, but prefer doctors to be in control

Sign In

Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial

This is a preview of subscriber content

Latest Video

Most Read

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race

Vaxxas appoints global vaccine leader to board as needle-free patch moves toward market

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

New Zealand accelerates medicines reform with major regulatory changes

Follow Us

New Stories

Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial

Australia joins global WHO task force to tackle antimicrobial resistance

New post-market review workplan focuses on real-world data and patient outcomes

Government adds new first-line treatment to the PBS for deadly blood cancer

RAGE Biotech raises $29 million and appoints new leadership to advance precision RNA therapeutics

Nanosonics names new North American president ahead of CORIS launch

Australians open to AI in healthcare, but prefer doctors to be in control